# US 2013/0156737 A1 · Secretion System and Methods for its Use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0156737 A1
- Document ID: US20130156737A1
- Status: Published application
- Kind: A1
- Application number: 13/632,417
- Filed: 2012-10-01
- Published: 2013-06-20
- Earliest claimed: 2011-07-12
- Assignees: University of Washington through its Center for Commercialization
- Inventors: Joseph Mougous; Alistair Brian Russell; Michele LeRoux
- Web page: https://patentgrep.com/patent/US20130156737A1

## CPC

- A61K 38/164: {from bacteria}
- A61P 31/04: Antibacterial agents
- C07K 14/21: from Pseudomonadaceae (F)
- C12N 1/06: Lysis of microorganisms
- C12P 21/02: having a known sequence of two or more amino acids, e.g. glutathione
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/034: containing a motif for targeting to the periplasmic space of Gram negative bacteria as a soluble protein, i.e. signal sequence should be cleaved
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}

## Abstract

The present invention provides reagents and methods for inhibiting bacterial infection and abnormal cell growth, as well as for selection cloning of nucleic acid inserts.

## Claims

### Claim 1

A substantially purified type VI secretion exported (Tse) protein, selected from the group consisting of Tse1, Tse2, and Tse3.

### Claim 2 (depends on 1)

The substantially purified Tse protein of claim 1, wherein the Tse protein comprises a conjugate comprising the Tse protein and one or more of the following:
(a) a transduction domain;
(b) a targeting domain to carry the conjugate across a bacterial outer membrane to a periplasmic space;
(c) a phage capsid;
(d) a leader sequence.

### Claim at position 3

3-5. (canceled)

### Claim 6 (depends on 1)

A pharmaceutical composition comprising
(a) the substantially purified Tse protein or Tsi protein of claim 1; and
(b) a pharmaceutically acceptable carrier.

### Claim 7

A host cell comprising,
(a) a plurality of genes encoding proteins capable of forming a type 6 secretion system (T6SS); and
(b) a recombinant gene encoding a therapeutic polypeptide that can be secreted by the recombinant T6SS in the recombinant cell, wherein the recombinant gene is operatively linked to a regulatory sequence.

### Claim 8

A recombinant gene encoding a fusion polypeptide of
(a) a therapeutic polypeptide; and
(b) one or both of a VgrG polypeptide and a Hcp polypeptide.

### Claim 9

A recombinant fusion protein comprising
(a) a therapeutic polypeptide selected from the group consisting of bactericidal proteins group HA phospholipase A2, bactericidal/permeability-increasing protein, human peptidoglycan recognition proteins 3 and 4 (PGLYRP3 and PGLYRP4), Tse1, Tse2, and Tse3; and
(b) one or both of a VgrG polypeptide and a Hcp polypeptide.

### Claim 10 (depends on 9)

A pharmaceutical composition, comprising the recombinant fusion protein of claim 9 and a pharmaceutically acceptable carrier.

### Claim 11 (depends on 7)

A pharmaceutical composition, comprising
(a) the host cell of claim 7; and
(b) a pharmaceutically acceptable carrier.

### Claim 12

(canceled)

### Claim 13 (depends on 2)

A method for inhibiting bacterial growth, comprising contacting bacteria to be inhibited with an amount of the polypeptide of claim 2 effective to inhibit bacterial growth.

### Claim 14 (depends on 11)

A method for inhibiting bacterial growth, comprising contacting bacteria to be inhibited with an amount of the pharmaceutical composition of claim 11 effective to inhibit bacterial growth.

### Claim 15

(canceled)

### Claim 16

A method for improved biomolecule extraction from bacterial cells, comprising contacting the bacterial cells with an amount effective of Tse1 to lyse the bacterial cells during the extraction process.

### Claim 17

(canceled)

### Claim 18

A recombinant vector, comprising a first gene coding for type VI secretion exported protein 1 (Tse1) or, type VI secretion exported protein 1 (Tse3) wherein the first gene is operatively linked to a heterologous regulatory sequence.

### Claim 19 (depends on 18)

The recombinant vector of claim 18, wherein the vector comprises one or more unique restriction enzyme recognition sites, and wherein cloning of a nucleic acid insert into the one or more unique restriction enzyme recognition sites disrupts expression of the first gene.

### Claim 20 (depends on 18)

The recombinant vector of claim 18, wherein the recombinant vector comprises at least a first and a second recombination site flanking the first gene operatively linked to a regulatory sequence, wherein said first and second recombination sites do not recombine with each other.

### Claim at position 19

21-23. (canceled)

### Claim 24 (depends on 18)

A method for selectable cloning, comprising culturing the recombinant host cell of any one of claim 18 under conditions suitable for expression of Tse1 or Tse3 from the recombinant vector if no insert is present, and selecting those cells that grow as comprising recombinant vectors with the insert cloned into the expression vector.

### Claim at position 21

25-26. (canceled)

### Claim 27 (depends on 24)

The method of claim 24, wherein the recombinant host cell comprises a gene encoding Tse1, wherein the method comprises culturing the recombinant host cell under conditions suitable for expression of Tse1, and wherein the culture conditions comprise enriching for particular clones by killing off other quickly via Tse1 lytic activity.

### Claim at position 23

28-31. (canceled)

### Claim 32 (depends on 18)

A method for production of a cloning vector that lacks an insert, comprising culturing the recombinant host cell claim 18 under conditions suitable for vector replication and expression of Tse1 or Tse3, wherein the recombinant host cells further express a Tse1 or Tse3 antidote, and isolating vector from the host cells.

### Claim 33 (depends on 32)

The method of claim 32, wherein the Tse1 or Tse3 antidote comprises Tsi1 or Tsi3.

### Claim 34

A recombinant vector, comprising a nucleic acid encoding Tsi1 or Tsi3, wherein the nucleic acid is operatively linked to a regulatory sequence.

### Claim 35

A host cell comprising in its genome, a first recombinant gene coding for Tse1 or Tse3 operatively linked to a regulatory sequence.

### Claim at position 28

36-38. (canceled)

### Claim 39

A substantially purified protein, selected from the group consisting of Tsi1, Tsi2, and Tsi3.

### Claim 40

A method for improved biomolecule extraction from bacterial cells, comprising contacting the bacterial cells with an amount effective of Tse1 to lyse the bacterial cells during the extraction process.
